Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings and product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. In the year-to-date period, this Zacks Rank #3 (Hold) company's shares have lost 79.1% against 6.6% growth of the industry. The S&P 500 composite has also gained 21.9% in the ...